Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 7Recruiting 6Unknown 1Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 1328Neoplasms 998Carcinoma, Non-Small-Cell Lung 865Prostatic Neoplasms 730Colorectal Neoplasms 671Lung Neoplasms 553Leukemia, Myeloid, Acute 475Neoplasm Metastasis 427Pancreatic Neoplasms 426Carcinoma, Hepatocellular 407Ovarian Neoplasms 393Multiple Myeloma 393Stomach Neoplasms 383Recurrence 369Squamous Cell Carcinoma of Head and Neck 327Melanoma 295Uterine Cervical Neoplasms 288Brain Neoplasms 288Triple Negative Breast Neoplasms 273Glioblastoma 263Head and Neck Neoplasms 260Precursor Cell Lymphoblastic Leukemia-Lymphoma 256Endometrial Neoplasms 238Lymphoma 230Esophageal Neoplasms 226Rectal Neoplasms 224Sarcoma 213Carcinoma, Renal Cell 205Colonic Neoplasms 196Lymphoma, Large B-Cell, Diffuse 194

Interventions

enzalutamide 4Docetaxel 2pembrolizumab 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1abiraterone 1Prednisone 1PF06821497 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Interventional × Metastatic Castration-Resistant Prostate Cancer × Clear all
NCT06629779 2026-05-20

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer

Phase 3 Recruiting
900 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04986423 2026-05-08

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics

Phase 2 Recruiting
200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT07287150 2026-05-06

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06318273 2026-04-08

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1 Recruiting
230 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06531499 2025-12-31

RADIODOSE

Novartis

Phase 1 Recruiting
106 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡